Kalaris Therapeutics, Inc. (KLRS) AI Dilution Summary

Cash, cash equivalents and marketable securities were $93,538,000 at 2026-06-30, against estimated monthly burn of $3,682,000. The funding channel in place is an at-the-market program with TD Securities (USA) LLC (TD Cowen), authorised to $100,000,000, with $0 sold to date. Dilution here is driven primarily by that ATM program, which has $100,000,000 of remaining capacity.